CN Mobile Logo

Search form


ASCO Prostate Cancer

Prostate Cancer Highlights From ASCO 2017

Cancer Network presents exclusive coverage on prostate cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6. We bring you expert interviews and reports on the latest trials and scientific advances that are changing the way this malignancy is managed and treated.

ASCO Prostate Cancer

Germline genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will test positive for pathogenic gene variants.

Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.

Continued enzalutamide with abiraterone failed to improve PFS in men with metastatic castration-resistant prostate cancer who progressed on enzalutamide alone.

A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.

Androgen deprivation therapy can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to results of a phase III trial.

Combined therapy with abiraterone acetate/prednisone plus ADT significantly improved overall survival and radiographic progression-free survival among men with metastatic hormone-naive prostate cancer.

Abiraterone at the start of ADT for men with metastatic prostate cancer significantly improved overall survival and failure-free survival, with manageable toxicity.


Subscribe to ASCO Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.